GSK's ICOS Agonist Disappointment Another Setback For Anticancer Ambitions
Feladilimab Phase II Combination Study With Keytruda Halted
Executive Summary
GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.
You may also be interested in...
As Jounce’s Vopratelimab Fails, Door Opens For LILRB2 Inhibitor JTX-8064
Vopratelimab is the second major ICOS agonist program to fail since GSK halted studies of feladilimab last year, but an analyst pinned higher hopes on JTX-8064.
Crucial Information Coming On GSK's Investor Day Includes Consumer Health Spin-Out Details
Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.
Six Questions For GSK Ahead Of Crucial Investor Day
Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.